IP Library Granted Patent US 9,914,761
Granted Patent B2
US 9,914,761 · App. 14/796,827 · Granted Mar 13, 2018

Oligomers for TNF superfamily inhibition

Inventors: Steven Teitelbaum (St. Louis, MO); Daved Fremont (St. Louis, MO); Julia T. Warren (St. Louis, MO); Christopher Nelson (St. Louis, MO)
Assignee: Washington University
C07K14/70575A61K38/00C07K2319/00C07K2319/02C07K2319/21C07K2319/23C07K2319/30C07K2319/50C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,914,761
App. No.
14/796,827
Granted
Mar 13, 2018
Kind
B2
Abstract

Methods for constructing efficient inhibitors of target TNF superfamily receptors, single chain target TNF superfamily ligands that inhibit of target TNF superfamily receptors while failing to engage or inhibit non-target TNF superfamily receptors, and methods of their use to treat diseases are provided. Single chain RANKL, TNF, and TRAIL ligands that effectively inhibit their target receptors while failing to inhibit non-target TNF superfamily receptors are also provided.

Claims (6)

1. A recombinant single chain polypeptide comprising:

(i) a first mutated Receptor Activator of Nuclear Factor κ B Ligand (RANKL) monomer comprising amino acid residues 1-159 of SEQ ID NO:15; and

(ii) two second mutated RANKL monomers which each comprise amino acid residues 172-327 of SEQ ID NO:15; wherein the three mutated RANKL monomers are operably linked in the recombinant single chain polypeptide and wherein the recombinant single chain polypeptide is an inhibitor of Receptor Activator of Nuclear Factor κ B (RANK).

2. The recombinant single chain polypeptide of claim 1 , wherein the recombinant single chain polypeptide comprises the amino acid sequence of SEQ ID NO:15.

3. A composition comprising the recombinant single chain polypeptide of claim 1 and a pharmaceutically acceptable excipient.

4. The composition of claim 3 , wherein the recombinant single chain polypeptide comprises the amino acid sequence of SEQ ID NO:15.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 22, 2016
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039113/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2015
From: TEITELBAUM, STEVEN; FREMONT, DAVED; NELSON, CHRISTOPHER; WARREN, JULIA
To: WASHINGTON UNIVERSITY
Reel/Frame 036190/0395 →
Continuity (2)
Provisional Application 62023117 · Jul 10, 2014
Related Publication 20160009783A1 · Jan 14, 2016